Real-world safety and healthcare resource utilization (HCRU) of lurbinectedin (lurbi) in patients (pts) with small cell lung cancer (SCLC): Jazz EMERGE 402 updated analysis.

被引：0
|
作者：
Badin, Firas Benyamine
Lammers, Philip Edward
Patel, Mehul P.
Shunyakov, Leonid
Slater, Dennis
Labbe, Catherine
Naveh, Navit
Boccuti, Anne
Hanvesakul, Raj
Li, Wenyan
Rengarajan, Badri
Halmos, Balazs
机构：
[1] Baptist Hlth Med Grp, Lexington, KY USA
[2] Baptist Canc Ctr, Memphis, TN USA
[3] Rochester Reg Hlth, Rochester, NY USA
[4] Carrie J Babb Canc Ctr, Bolivar, MO USA
[5] Eastern Connecticut Hematol & Oncol Associates, Norwich, CT USA
[6] Univ Laval, Ctr Rech, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada
[7] Jazz Pharmaceut, Philadelphia, PA USA
[8] Jazz Pharmaceut, Oxford, England
[9] Jazz Pharmaceut, Palo Alto, CA USA
[10] Montefiore Einstein Comprehens Canc Ctr, Bronx, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e23266
引用
收藏
页数：1
相关论文
共 50 条
  • [21] REAL-WORLD HEALTHCARE COSTS IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER IN ITALY
    Danesi, V
    Massa, I
    Altini, M.
    Balzi, W.
    Gentili, N.
    Foca, F.
    Manunta, S.
    Ejzykowicz, F.
    Delmonte, A.
    VALUE IN HEALTH, 2019, 22 : S451 - S451
  • [22] REAL-WORLD TREATMENT PATTERNS, HEALTHCARE COSTS, AND HEALTHCARE RESOURCE UTILIZATION IN PATIENTS IN THE US WITH METASTATIC NON-SMALL CELL LUNG CANCER RECEIVING SYSTEMIC ANTICANCER THERAPY
    Chopra, D.
    Waterhouse, D. M.
    Sultan, I
    Lonshteyn, A.
    Delea, T. E.
    Stollenwerk, B.
    VALUE IN HEALTH, 2024, 27 (06) : S374 - S374
  • [23] REAL-WORLD UTILIZATION OF BRIGATINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Lin, H. M.
    Pan, X.
    Hou, P.
    Huang, H.
    Baumann, P.
    Jahanzeb, M.
    VALUE IN HEALTH, 2019, 22 : S115 - S115
  • [24] CLINICAL ACTIVITY OF LURBINECTEDIN (PM01183) IN COMBINATION WITH DOXORUBICIN (DOX) IN SMALL CELL LUNG CANCER (SCLC) PATIENTS (PTS): PRELIMINARY RESULTS OF A PHASE IB STUDY SUBPOPULATION ANALYSIS.
    Forster, M.
    Calvo, E.
    Szyldergemajn, S.
    Boni, V.
    Benafif, S.
    Fernandez, C.
    Turnbull, S.
    Cubillo, A.
    Flynn, M.
    Velasco Sampayo, A.
    Soto Matos-Pita, A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S633 - S633
  • [25] Real-World Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Early-Stage Non-Small-Cell Lung Cancer
    O'Sullivan, Dylan E.
    Boyne, Devon J.
    Ford-Sahibzada, Chelsea
    Inskip, Jessica A.
    Smith, Christopher J.
    Sripada, Kaushik
    Brenner, Darren R.
    Cheung, Winson Y.
    CURRENT ONCOLOGY, 2024, 31 (01) : 447 - 461
  • [26] Safety of pembrolizumab in patients with non-small cell lung cancer: a real-world study
    Thakrar, D. B.
    Essang, B.
    Echlin, A.
    Murdock, C.
    Lind, M. J.
    LUNG CANCER, 2019, 127 : S40 - S41
  • [27] Real-world treatment patterns, survival, and cost among elderly patients with small-cell lung cancer (SCLC).
    Shao, Changxia
    He, Jinghua
    Kachroo, Sumesh
    Jin, Fan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in patients (Pts) with relapsed small cell lung cancer (SCLC): Results from a phase 2 expansion cohort.
    Paz-Ares, Luis G.
    Gonzalez, Alejandro Falcon
    Navarro, Alejandro
    Sanchez-Gastaldo, Amparo
    Cote, Gregory Michael
    Bockorny, Bruno
    Molina-Cerrillo, Javier
    Artal, Angel
    Baena, Javier
    Gil, Ana
    Aix, Santiago Ponce
    de Cabo, Helena Bote
    Martinez, Sara
    Martinez, Julia Martinez
    Lopez-Vilarino, Jose Antonio
    Kahatt, Carmen Maria
    Zeaiter, Ali Hassan
    Gomez, Javier
    Zugazagoitia, Jon
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Real-World Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the US
    Chopra, Divyan
    Waterhouse, David M.
    Sultan, Ihtisham
    Stollenwerk, Bjorn
    CURRENT ONCOLOGY, 2025, 32 (03)
  • [30] Impact of broadening clinical trial eligibility criteria for advanced non small cell lung cancer patients: Real-world analysis.
    Harvey, R. Donald
    Rubinstein, Wendy S.
    Ison, Gwynn
    Khozin, Sean
    Chen, Li
    Miller, Robert S.
    Jun, Monika
    Stepanski, Edward
    Hyde, Brigham
    Uldrick, Thomas S.
    Komatsoulis, George Anthony
    Roberts, Jeremy
    Garrett-Mayer, Elizabeth
    Schilsky, Richard L.
    Schenkel, Caroline
    Kim, Edward S.
    Bruinooge, Suanna S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
12345